drugset
Drugs / AAV human Factor IX vector
last change Jan 2004 re-read 3 minutes ago

AAV human Factor IX vector

Gene therapy (AAV / viral vector)

Developed for
hemophilia B
Investigated by
Avigen · Children's Hospital of Philadelphia · Christian Medical College, Vellore, India · Royal Prince Alfred Hospital, Sydney, Australia · Stanford University · The Hemophilia Center of Western Pennsylvania
+3 more · The University of Texas Health Science Center, Houston · University of Campinas, Brazil · University of Washington

Trials 1

today NCT00076557 · Ph 1/2
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00076557 Jan 2004 → ? hemophilia B Avigen Terminated No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AAV human Factor IX vector “In this study, AAV human Factor IX vector will be injected into the liver using a catheter inserted into a large blood vessel” NCT00076557 ↗
Action Restore “will be used to transfer a normal gene for human clotting factor IX into patients with severe hemophilia B” NCT00076557 ↗
Modality Gene therapy (AAV / viral vector) “a modified virus called adeno-associated virus (AAV) will be used to transfer a normal gene for human clotting factor IX” NCT00076557 ↗
Route Other “will be injected into the liver using a catheter inserted into a large blood vessel” NCT00076557 ↗